CentoCard\u00ae<\/a>, seu kit propriet\u00e1rio e validado de coleta de sangue seco em papel filtro, para identificar pacientes com DP que apresentam muta\u00e7\u00e3o no gene LRRK2 para recrutamento nos ensaios cl\u00ednicos da Denali.<\/p>\nMuta\u00e7\u00f5es no gene LRRK2 s\u00e3o uma das causas gen\u00e9ticas mais conhecidas da doen\u00e7a de Parkinson e um fator determinante da disfun\u00e7\u00e3o lisossomal, que contribui para a forma\u00e7\u00e3o de agregados proteicos dos corpos de Lewy e para a neurodegenera\u00e7\u00e3o.<\/p>\n
\u201cNossa colabora\u00e7\u00e3o exclusiva refor\u00e7a a forte capacidade da CENTOGENE de acelerar a identifica\u00e7\u00e3o precoce de pacientes com doen\u00e7as gen\u00e9ticas raras em todo o mundo. Como l\u00edder no fornecimento de informa\u00e7\u00f5es gen\u00e9ticas sobre doen\u00e7as raras, acreditamos que podemos contribuir para o desenvolvimento de medicamentos modificadores da doen\u00e7a para pacientes com doen\u00e7a de Parkinson pela Denali. A CENTOGENE ajudar\u00e1 a Denali a acelerar o recrutamento de pacientes para estudos cl\u00ednicos de seu programa LRRK2\u201d, disse o Dr. Arndt Rolfs, CEO e fundador da CENTOGENE.<\/p>\n
\u201cA Denali \u00e9 a primeira empresa a realizar ensaios cl\u00ednicos com inibidores de LRRK2 para o tratamento da doen\u00e7a de Parkinson. Esta parceria com a CENTOGENE \u00e9 fundamental para os nossos esfor\u00e7os globais de identifica\u00e7\u00e3o e recrutamento de pacientes com Parkinson que apresentem muta\u00e7\u00e3o no gene LRRK2 para os nossos estudos cl\u00ednicos planejados\u201d, afirmou Carole Ho, MD, Diretora M\u00e9dica e Chefe de Desenvolvimento da Denali. \u201cEstamos impressionados com a abordagem e a tecnologia da CENTOGENE e acreditamos que os nossos esfor\u00e7os conjuntos ir\u00e3o acelerar o recrutamento de pacientes com Parkinson e a conclus\u00e3o dos nossos ensaios cl\u00ednicos.\u201d<\/p>","protected":false},"excerpt":{"rendered":"
A CENTOGENE e a Denali Therapeutics (NASDAQ: DNLI) anunciaram hoje uma colabora\u00e7\u00e3o estrat\u00e9gica para a identifica\u00e7\u00e3o e o recrutamento global de pacientes com doen\u00e7a de Parkinson (DP) com muta\u00e7\u00e3o LRRK2.<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-2402","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"\n
CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials | CENTOGENE<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.centogene.com\/pt\/a-centogene-e-a-denali-therapeutics-anunciam-colaboracao-estrategica-para-recrutar-pacientes-com-mutacao-no-gene-lrrk2-para-ensaios-clinicos\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials | CENTOGENE\" \/>\n<meta property=\"og:description\" content=\"CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2-positive Parkinson\u2019s disease (PD) patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.centogene.com\/pt\/a-centogene-e-a-denali-therapeutics-anunciam-colaboracao-estrategica-para-recrutar-pacientes-com-mutacao-no-gene-lrrk2-para-ensaios-clinicos\/\" \/>\n<meta property=\"og:site_name\" content=\"CENTOGENE\" \/>\n<meta property=\"article:published_time\" content=\"2018-10-02T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"740\" \/>\n\t<meta property=\"og:image:height\" content=\"416\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"admincg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"admincg\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/\"},\"author\":{\"name\":\"admincg\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\"},\"headline\":\"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials\",\"datePublished\":\"2018-10-02T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/\"},\"wordCount\":306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"articleSection\":[\"Uncategorized\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/\",\"name\":\"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials | CENTOGENE\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\"},\"datePublished\":\"2018-10-02T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.centogene.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#website\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"name\":\"CENTOGENE\",\"description\":\"Guiding Precision Medicine\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.centogene.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#organization\",\"name\":\"CENTOGENE\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"contentUrl\":\"https:\\\/\\\/www.centogene.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/CENTOGENE-Flower.png\",\"width\":246,\"height\":246,\"caption\":\"CENTOGENE\"},\"image\":{\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/centogene\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UClZxtN_laC1_ZtCdxkasdPQ\",\"https:\\\/\\\/www.instagram.com\\\/_centogene_\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.centogene.com\\\/#\\\/schema\\\/person\\\/d9b8738539a9ddb5de5a02a909d40b8b\",\"name\":\"admincg\",\"url\":\"https:\\\/\\\/www.centogene.com\\\/pt\\\/author\\\/admincg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CENTOGENE e DENALI THERAPEUTICS anunciam colabora\u00e7\u00e3o estrat\u00e9gica para recrutar pacientes com muta\u00e7\u00e3o no gene LRRK2 para ensaios cl\u00ednicos | CENTOGENE","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.centogene.com\/pt\/a-centogene-e-a-denali-therapeutics-anunciam-colaboracao-estrategica-para-recrutar-pacientes-com-mutacao-no-gene-lrrk2-para-ensaios-clinicos\/","og_locale":"pt_BR","og_type":"article","og_title":"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials | CENTOGENE","og_description":"CENTOGENE and Denali Therapeutics (NASDAQ: DNLI) today announced a strategic collaboration for the global identification and recruitment of LRRK2-positive Parkinson\u2019s disease (PD) patients.","og_url":"https:\/\/www.centogene.com\/pt\/a-centogene-e-a-denali-therapeutics-anunciam-colaboracao-estrategica-para-recrutar-pacientes-com-mutacao-no-gene-lrrk2-para-ensaios-clinicos\/","og_site_name":"CENTOGENE","article_published_time":"2018-10-02T00:00:00+00:00","og_image":[{"width":740,"height":416,"url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2025\/03\/csm_centogene-diagnostics-priority-disease-03_5a57c07603.webp","type":"image\/webp"}],"author":"admincg","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"admincg","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/"},"author":{"name":"admincg","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b"},"headline":"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials","datePublished":"2018-10-02T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/"},"wordCount":306,"commentCount":0,"publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"articleSection":["Uncategorized"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/","url":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/","name":"CENTOGENE e DENALI THERAPEUTICS anunciam colabora\u00e7\u00e3o estrat\u00e9gica para recrutar pacientes com muta\u00e7\u00e3o no gene LRRK2 para ensaios cl\u00ednicos | CENTOGENE","isPartOf":{"@id":"https:\/\/www.centogene.com\/#website"},"datePublished":"2018-10-02T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.centogene.com\/centogene-and-denali-therapeutics-announce-strategic-collaboration-to-recruit-lrrk2-patients-for-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.centogene.com\/"},{"@type":"ListItem","position":2,"name":"CENTOGENE and DENALI THERAPEUTICS announce strategic collaboration to recruit LRRK2 patients for clinical trials"}]},{"@type":"WebSite","@id":"https:\/\/www.centogene.com\/#website","url":"https:\/\/www.centogene.com\/","name":"CENTOGENE","description":"Orientando a Medicina de Precis\u00e3o","publisher":{"@id":"https:\/\/www.centogene.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.centogene.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.centogene.com\/#organization","name":"CENTOGENE","url":"https:\/\/www.centogene.com\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","contentUrl":"https:\/\/www.centogene.com\/wp-content\/uploads\/2026\/04\/CENTOGENE-Flower.png","width":246,"height":246,"caption":"CENTOGENE"},"image":{"@id":"https:\/\/www.centogene.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/centogene","https:\/\/www.youtube.com\/channel\/UClZxtN_laC1_ZtCdxkasdPQ","https:\/\/www.instagram.com\/_centogene_\/"]},{"@type":"Person","@id":"https:\/\/www.centogene.com\/#\/schema\/person\/d9b8738539a9ddb5de5a02a909d40b8b","name":"admincg","url":"https:\/\/www.centogene.com\/pt\/author\/admincg\/"}]}},"_links":{"self":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/comments?post=2402"}],"version-history":[{"count":0,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/posts\/2402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/media?parent=2402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/categories?post=2402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.centogene.com\/pt\/wp-json\/wp\/v2\/tags?post=2402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}